OnKure Therapeutics, Inc
Price
FilingsNewest: 8-K, Director or officer changeAug 12 →InsidersNo open-market buys. 2 insiders sold $4,477, 0 of 6 sales on a 10b5-1 plan.→HoldersRa 29.2%BVF Inc/il 23.7%Acorn Capital 20.8%→Financing →PeersClosest companies: PRLD, TYRA, PMVP→
From the filings
Figures
- Net income
- −$58.7Mlast 12 months
- Operating cash flow
- −$50.8Mlast 12 months
- Cash and equivalents
- $166.5Mat the last balance sheet
- Shares outstanding
- 13.7M shareson issue